Jump to main content
Jump to site search

Issue 33, 2017
Previous Article Next Article

Two decades of antifilarial drug discovery: a review

Author affiliations

Abstract

Filariasis is one of the oldest, most debilitating, disabling, and disfiguring neglected tropical diseases with various clinical manifestations and a low rate of mortality, but has a high morbidity rate, which results in social stigma. According to the WHO estimation, about 120 million people from 81 countries are infected at present and an estimated 1.34 billion people live in areas endemic to filariasis and are at risk of infection. In this review, we focus on Lymphatic Filariasis (LF) and provide brief insights on some other filarial conditions. Current drug treatments have beneficial effects in the elimination of only the larval stage of the worms. Very few drugs are available for treatment of filariasis but their repetitive use may give rise to drug resistance. They are also found to be fairly ineffective towards eliminating adult worms. Moreover, no effective vaccine is available for treatment of filariasis. Because of these limitations, development of new antifilarials has been of utmost importance, a fact which encourages researchers to discover new drugs having antifilarial activity. Herein we extensively review developments in the field of antifilarials including the types of filariasis, their historical perspectives, eradication programs, different classes of drug (i.e. synthetic as well as natural), explored product-derived different targets, patents and clinical trials.

Graphical abstract: Two decades of antifilarial drug discovery: a review

Back to tab navigation

Article information


Submitted
14 Feb 2017
Accepted
31 Mar 2017
First published
11 Apr 2017

This article is Open Access

RSC Adv., 2017,7, 20628-20666
Article type
Review Article

Two decades of antifilarial drug discovery: a review

J. N. Sangshetti, D. B. Shinde, A. Kulkarni and R. Arote, RSC Adv., 2017, 7, 20628
DOI: 10.1039/C7RA01857F

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. Material from this article can be used in other publications provided that the correct acknowledgement is given with the reproduced material.

Reproduced material should be attributed as follows:

  • For reproduction of material from NJC:
    [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the Centre National de la Recherche Scientifique (CNRS) and the RSC.
  • For reproduction of material from PCCP:
    [Original citation] - Published by the PCCP Owner Societies.
  • For reproduction of material from PPS:
    [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the European Society for Photobiology, the European Photochemistry Association, and RSC.
  • For reproduction of material from all other RSC journals:
    [Original citation] - Published by The Royal Society of Chemistry.

Information about reproducing material from RSC articles with different licences is available on our Permission Requests page.


Social activity

Search articles by author

Spotlight

Advertisements